May 17, 2022

Generation of Potent and High-Yield Exosome-Associated AAV (exoAAV) Using Engineered Exosomes

Codiak presented new preclinical data at the American Society of Gene and Cell Therapy (ASGCT) 2022 on the Company’s engEx-AAV™ discovery program, a novel strategy that aims to leverage exosomes to improve adeno-associated virus (AAV) vector gene therapy. The data demonstrate that engineering exosomes to encapsulate AAV results in increased yield, resists antibody neutralization in vitro and retains transduction ability.

April 20, 2022

Exosome-based antigen-specific vaccine platform

Codiak presented new preclinical data at the World Vaccine Congress 2022 demonstrating the potential for a novel engineered exosome-based vaccine candidate derived from the exoVACC™ platform to induce cross-neutralizing antibody protection against multiple strains of coronaviruses and an antigen-specific and comprehensive immune response against structurally conserved regions of multiple coronavirus variants.

April 8, 2022

Exosome-mediated delivery of antisense oligonucleotides targeting C/EBPβ reprograms tumor-associated macrophages and induces potent single agent anti-tumor activity

Codiak presented preclinical data at the American Association for Cancer Research (AACR) Annual Meeting on exoASO-C/EBPβ, an engineered exosome therapeutic candidate designed to precisely target a key oncogenic transcription factor in order to induce an anti-tumor immune response.

February 18, 2022

Exosome mediated genetic reprogramming of tumor associated macrophages by exoASO-STAT6 leads to potent monotherapy anti-tumor efficacy

Publication of data from the preclinical program of exoASO-STAT6 for the Treatment of Primary and Metastatic Hepatic Cancers in the American Association for the Advancement of Science’s journal, Science Advances.

December 2, 2021

ExoVACC: An exosome-based vaccine platform for the development of SARS-CoV-2 vaccine

Codiak presented preclinical data at the World Vaccine & Immunotherapy Congress 2021 showing the potential of Codiak's novel vaccine candidate for SARS-CoV-2 to generate broad immunogenicity and neutralization against multiple variants.

November 12, 2021

Exosome reprogramming of tumor associated macrophages by exoASO-STAT6 for the treatment of hepatocellular carcinoma (HCC)

Codiak presented additional preclinical data at the Annual Meeting of the Society for Immunotherapy of Cancer (SITC) demonstrating unique monotherapy activity with systemic dosing with exoASO-STAT6, supporting planned clinical studies in hepatocellular carcinoma and myeloid rich tumors.

November 12, 2021

Combination therapy of exoSTING and exoIL-12 activates systemic anti-tumor immunity

Codiak presented preclinical data at the Annual Meeting of the Society for Immunotherapy of Cancer (SITC) that show that the combination of exoSTING and exoIL-12 generated an abscopal effect in solid tumor preclinical models and achieved 100% complete responses when dosed with anti-PD-1 checkpoint inhibitor.

November 12, 2021

exoSTING demonstrates potent anti-tumor activity in a mouse model of leptomeningeal disease

Codiak presented data at the Annual Meeting of the Society for Immunotherapy of Cancer (SITC) that show exoSTING monotherapy suppressed tumor growth and improved survival in preclinical models of leptomeningeal disease.

May 11, 2021

Engineering exosomes with altered cellular tropism for neuronal cell targeting

Codiak presented data at the Annual Meeting of the American Society for Gene and Cell Therapy demonstrating that exosomes engineered to express different targeting ligands at high density result in increased uptake in various cell types of interest in the nervous system.

May 11, 2021

exoVACC, a novel exosome-based vaccine platform that induces robust, tunable cellular and humoral immune responses in animal models

Codiak presented data at the Annual Meeting of the American Society of Gene and Cell Therapy demonstrating the potential for Codiak's proprietary and modular vaccine system to generate antigen-specific immune responses that can be modulated through antigen orientation and adjuvant loading.

May 11, 2021

Engineered exosomes efficiently deliver STAT6 antisense oligonucleotides to tumor associated macrophages (TAMs) resulting in potent, local and systemic anti-tumor activity

Codiak presented data at the Annual Meeting of the American Society of Gene and Cell Therapy that show exoASO-STAT6 effectively reprograms immunosuppressive macrophages to a pro-inflammatory phenotype and results in dose-dependent single-agent activity in multiple tumor models.

May 11, 2021

Optimization of AAV loading into extracellular vesicles as a method to avoid neutralizing antibodies

Codiak presented data at the Annual Meeting of the American Society of Gene and Cell Therapy that show that AAV encapsulated in an exosome (exoAAV) results in increased potency compared to "free" AAV and resistance to neutralizing antibodies.

April 22, 2021

exoSTING, an extracellular vesicle loaded with STING agonists, promotes tumor immune surveillance

Publication of data from the preclinical program of exoSTING for the treatment of cancer in Communications Biology, a Nature Research publication.

April 10, 2021

Randomized placebo-controlled Phase 1 trial in healthy volunteers investigating safety, PK and PD of exoIL-12 - a novel engineered exosome therapeutic candidate

Codiak presented data at the American Association for Cancer Research (AACR) Annual Meeting from the Phase 1 clinical trial of exoIL-12 demonstrating local pharmacology, tolerability and absence of systemic exposure in healthy volunteers

April 10, 2021

Engineered exosome-mediated STAT6 knockdown in tumor associated macrophages (TAMS) results in potent single agent activity in a hepatocellular carcinoma (HCC) model

Codiak presented preclinical data on its exoASO-STAT6 program at the American Association for Cancer Research (AACR) Annual Meeting

March 1, 2021

Exosome surface display of IL-12 results in tumor-retained pharmacology with superior potency and limited systemic exposure compared with recombinant IL-12

Publication of the data from the preclinical development program of exoIL-12 for the treatment of cancer in Molecular Cancer Therapeutics, a journal of the American Association for Cancer Research.

March 1, 2021

In-vitro evaluation of [3H]CPPC as a tool radioligand for CSF-1R suggests it may have a limited utility as an in-vivo CNS imaging probe

Publication of the assessment of a CSF1R radioligand in tissue from neuroinflammation models in ACS Chemical Neuroscience, a journal of the American Chemical Society.

January 21, 2021

A versatile platform for generating engineered extracellular vesicles with defined therapeutic properties

Publication in Molecular Therapy, a journal of the American Society of Gene and Cell Therapy, describing the identification and characterization of two novel exosome-associated proteins, PTGFRN and BASP1, that enable Codiak’s proprietary engEx Platform and facilitate precise design and engineering of exosomes for potential therapeutic purposes.

November 9, 2020

Exosome surface display of IL-12 results in tumor-retained pharmacology with superior potency and limited systemic exposure in non-human primates

Codiak presented preclinical data on its exoIL-12 program via a poster presentation at the Annual Meeting of the Society for the Immunotherapy of Cancer (SITC)

November 9, 2020

Engineered exosomes with altered cellular tropism achieve targeted STING agonist delivery and single-agent tumor control in vivo

Codiak presented data at the Annual Meeting of the Society for the Immunotherapy of Cancer (SITC) demonstrating the ability of the engEx Platform to alter cellular tropism and increase functional payload delivery in multiple immune cell types.

June 23, 2020

Genetic reprogramming of TAMS by engineered exosomes results in potent single agent anti-tumor activity

Codiak presented preclinical data on its exoASO-STAT6 and exoASO-C/EBPβ programs via an oral presentation at the American Association For Cancer Research (AACR) 2020 Virtual Annual Meeting II

May 14, 2020

Site specific integration enables rapid cell line engineering for the development of precision exosome based therapeutics

Codiak presented data at the 23rd Annual Meeting of the American Society of Gene and Cell Therapy demonstrating the feasibility to manufacture therapeutic engineered exosomes from site specific integration

May 14, 2020

Exosome mediated delivery of antisense oligonucleotides reprograms tumor associated macrophages and induces anti-tumor responses

Codiak presented data at the 23rd Annual Meeting of the American Society of Gene and Cell Therapy demonstrating that exoASOs against C/EBPβ represent a first-in-class strategy to reprogram tumor-associated
myeloid cells in a highly selective manner.

May 13, 2020

Multifunctional Exosome Construction by Precision Cell Engineering

Codiak presented data at the 23rd Annual Meeting of the American Society of Gene and Cell Therapy demonstrating that the engEx platform is effective for the precision engineering of multifunctional exosomes.

November 18, 2019

Codak Biosciences | Reprogramming of tumor-associated M2 macrophages with antisense oligonucleotides-loaded exosomes results in potent single-agent antitumor activity

Codiak presented data at the American Association for Cancer Research’s Special Conference on Tumor Immunology and Immunotherapy demonstrating the potential of engineered exosomes incorporating an antisense oligonucleotide (ASO) to selectively reprogram tumor-associated macrophages and generate potent anti-tumor activity.

November 8, 2019

Codiak BioSciences | Exosome Surface Display of IL-12 Results in Tumor-Retained Pharmacology with Superior Potency and Limited Systemic Exposure Compared to Recombinant IL-12

Codiak presented data at The Society for Immunotherapy of Cancer (SITC) supporting that exoIL-12 demonstrates tumor-retained and dose-dependent pharmacology with superior anti-tumor efficacy compared to soluble recombinant IL-12.

November 8, 2019

Codiak BioSciences | Selective Activation of Antigen Presenting Cells by exoSTING Enhances Tumor Antigen-Specific Immune Response

Codiak presented data at The Society for Immunotherapy of Cancer (SITC) demonstrating that exoSTING shows unique pharmacodynamic effects and tumor antigen-specific systemic immune responses compared to free STING agonist.

April 29, 2019

Codiak BioSciences | Development of a platform for exosome engineering using a novel and selective scaffold protein for surface display

Codiak presented data supporting the identification of a novel and selective scaffold protein, PTGFRN, as part of its engEX exosome platform at the Annual Meeting of the International Society for Extracellular Vesicles (ISEV).

April 1, 2019

Codiak BioSciences | engEx™: A novel exosome engineering platform enabling targeted transfer of pharmacological molecules

Codiak presented data supporting the potential of its engEX™ Platform and its proprietary PTGFRN protein scaffold at the 2019 American Association for Cancer Research (AACR) Annual Meeting.

March 13, 2019

Codiak BioSciences | Developing an Engineered Exosome Therapeutic Platform for Immuno-Oncology

Codiak presented preclinical data in support of its engEx Platform for engineering exosomes at the Keystone Symposium on Cancer Immunotherapy.

November 9, 2018

Codiak BioSciences | Selective delivery of exosome-mediated STING agonist to antigen presenting cells results in significantly improved potency and reduced toxicity

Codiak presented results from preclinical studies demonstrating the potential efficacy of exoSTING™, a novel engineered exosome product candidate targeting checkpoint refractory tumors at the Society for Immunotherapy of Cancer (SITC)’s 33rd Annual Meeting.